» Articles » PMID: 9368765

Hematopoietic Stem Cells Expand During Serial Transplantation in Vivo Without Apparent Exhaustion

Overview
Journal Curr Biol
Publisher Cell Press
Specialty Biology
Date 1997 Nov 22
PMID 9368765
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Whether hematopoietic stem cells can proliferate without limit, or whether their regenerative capacity declines with repeated division, has been debated for decades. Prevailing opinion favours an intrinsic 'decline', a view based on the finite degree to which murine bone marrow can be serially transplanted, the diminished self-renewal of spleen colony-forming cells (CFU-s) subjected to repeated passage, and the failure of stem cells to regenerate to normal levels after even a single transplantation. However, serial transfer experiments did not specifically monitor input and output of long-lived stem cells (long-term reconstituting cells, LTRCs), leaving competing interpretations unresolved. We have re-examined the issue by quantitating 7-12 month LTRCs during sequential transplantations. Although these cells recovered to only 4% of normal levels after primary bone marrow transplantation, at each passage they increased around 10-fold relative to the amount transplanted, attaining an estimated cumulative expansion of 8400-fold over the original input after four transfers. Expansion was limited by transfer of increasing numbers of marrow cells and specifically of LRTCs, suggesting an extrinsically determined ceiling to stem cell growth. Conversely, expansion was enhanced in vivo by administration of stem cell factor (SCF, c-kit ligand) and interleukin-11. The results challenge the view that expansion of passaged stem cells is limited by exhaustion, and indicate that augmentation after transplant is limited by extrinsic mechanisms whose effects are reversible either by further transfer of the stem cells into irradiated hosts or by administration of exogenous cytokines.

Citing Articles

Graft conditioning with fluticasone propionate reduces graft-versus-host disease upon allogeneic hematopoietic cell transplantation in mice.

Varady E, Ayala L, Nguyen P, Scarfone V, Karimzadeh A, Zhou C EMBO Mol Med. 2023; 15(9):e17748.

PMID: 37538042 PMC: 10493574. DOI: 10.15252/emmm.202317748.


How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance.

Ciccone V, Morbidelli L, Ziche M, Donnini S Cancer Drug Resist. 2022; 3(1):26-37.

PMID: 35582039 PMC: 9086516. DOI: 10.20517/cdr.2019.70.


Gene therapy of Csf2ra deficiency in mouse fetal monocyte precursors restores alveolar macrophage development and function.

Li F, Okreglicka K, Piattini F, Pohlmeier L, Schneider C, Kopf M JCI Insight. 2022; 7(7).

PMID: 35393945 PMC: 9057586. DOI: 10.1172/jci.insight.152271.


Glucose Metabolism and Aging of Hematopoietic Stem and Progenitor Cells.

Poisa-Beiro L, Landry J, Raffel S, Tanaka M, Zaugg J, Gavin A Int J Mol Sci. 2022; 23(6).

PMID: 35328449 PMC: 8955027. DOI: 10.3390/ijms23063028.


Development of a novel and synthetic HematoMiR technology that broadly modulates quiescence of stem cells and enhances HSC expansion.

Uslu M, Kocabas F Cell Mol Life Sci. 2021; 79(1):68.

PMID: 34971431 PMC: 11072120. DOI: 10.1007/s00018-021-04031-1.